Lokelma
(Sodium Zirconium Cyclosilicate)Phase 3
AstraZenecaLokelma is one of 7 small molecule programs targeting Chronic Kidney Diseases. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Chronic Kidney Diseases
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Jardiance
Boehringer IngelheimApproved
Sodium Valproate
AstraZenecaPhase 3
Ozempic
Novo NordiskPhase 2
Lokelma
AstraZenecaPhase 3
Definity
MMicrovascular Therapeutics, LLC
Phase 2
Farxiga
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Kidney Diseases1 trial
Phase III, Multicenter, Open-label, Randomized Clinical Trial to Evaluate Efficacy of Sodium Zirconium Cyclosilicate (Lokelma) Compared to Standard of Care to Manage Hyperkalemia in Patients With Chronic Kidney Disease (CKD)
Recruiting·FFundación para la Investigación del Hospital Clínico de Valencia·Phase 3·NCT06578533·78 enrolled
Regulatory
FDA Approval Timeline[4]
May 18, 2018
LOKELMA
NDA NDA207078
Sources
References
- [1]
- [2]
- [3]
- [4]
- [5]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company